Our flagship therapy targets Critical Limb Ischemia (CLI) using iPSC-derived endothelial cells enhanced by cytokine signaling. This innovative “supercharged” approach boosts angiogenesis, restores blood flow, and modulates inflammation for tissue repair. Delivered through homologous injection, NBL-EC01-P offers a next-generation regenerative solution for patients with severe vascular disease where current treatments are limited.